Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8461 to 8475 of 8900 results

  1. Unstable angina and NSTEMI: early management (CG94)

    This guideline has been updated and replaced by NICE guideline NG185.

    Withdrawn guideline

  2. Neuropathic pain in adults: pharmacological management in non-specialist settings (CG96)

    This guidance has been updated and replaced by NICE guideline CG173.

    Withdrawn guideline

  3. Eating disorders in over 8s: management (CG9)

    This guidance has been updated and replaced by NICE guideline NG69.

    Withdrawn guideline

  4. Depression in adults: recognition and management (CG90)

    This guideline has been updated and replaced by NICE guideline on depression in adults: treatment and management (NG222).

    Withdrawn guideline

  5. Venous thromboembolism: reducing the risk for patients in hospital (CG92)

    This guidance has been updated and replaced by NICE guideline NG89.

    Withdrawn guideline

  6. Glaucoma: diagnosis and management (CG85)

    This guidance has been updated and replaced by NICE guideline NG81.

    Withdrawn guideline

  7. Coeliac disease: recognition and assessment (CG86)

    This guidance has been updated and replaced by NICE guideline NG20.

    Withdrawn guideline

  8. Type 2 diabetes: The management of type 2 diabetes (CG87)

    This guidance has been updated and replaced by NICE guideline NG28.

    Withdrawn guideline

  9. Low back pain in adults: early management (CG88)

    This guidance has been updated and replaced by NICE guideline NG59.

    Withdrawn guideline

  10. Asfotase alfa for treating paediatric-onset hypophosphatasia (HST6)

    This guidance has been updated and replaced by NICE highly specialised technologies guidance 23.

    Withdrawn guidance

  11. Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene (HST3)

    This guidance has been updated and replaced by NICE highly specialised technologies guidance 22.

    Withdrawn guidance

  12. Elosulfase alfa for treating mucopolysaccharidosis type IVa (HST2)

    This guidance has been updated and replaced by NICE’s highly specialised technologies guidance on elosulfase alfa for treating mucopolysaccharidosis type 4A (HST19).

    Withdrawn guidance

  13. Developing NICE guidelines: how to get involved (PMG22)

    October 2018: This process guide has been updated. The updated version can be found in the tools and resources for developing NICE guidelines: the manual.

    Withdrawn guide

  14. Process manual for the endorsement of guidance and quality standard support resources (PMG29)

    The endorsement programme is now closed and no new applications are being accepted. Information about existing endorsed resources, are available on the endorsement webpage. Please email endorsement@nice.org.uk if you have any queries.

    Withdrawn guide

  15. Medicines optimisation: key therapeutic topics – Integrated process statement (PMG13)

    February 2022: we have withdrawn our medicines optimisation: key therapeutic topics. We have taken this decision after reviewing the wide range of services we currently provide, so we can focus on delivering the priorities outlined in our 5-year strategy. If you have any queries, please contact nice@nice.org.uk.

    Withdrawn guide